Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure. - Open‑angle glaucoma: reduces intraocular pressure to slow disease progression. - Ocular hypertension: lowers pressure to prevent conversion to glaucoma. - Secondary glaucoma (e.g., pseudoexfoliative): helps control intraocular pressure when other causes are present.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: foreign‑body sensation or mild discomfort. - Blurred vision: temporary visual disturbance after instillation. - Periocular skin darkening: hyperpigmentation around the eye.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Significant vision changes: sudden loss of vision or visual field defects. - Ocular infection: increased risk if sterility is compromised. - Systemic hypersensitivity: rare anaphylactic response.

Before using Latanoprost, consider the following safety measures. - Monitor IOP: regular pressure measurements to assess efficacy. - Assess for ocular inflammation: avoid use during active uveitis. - Avoid use with active eye infection: may exacerbate condition. - Caution in patients with a history of uveitis: increased risk of flare‑ups. - Pregnancy and lactation: safety unknown; prescribe only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: additive IOP reduction may cause hypotony. - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost effectiveness. - Systemic carbonic anhydrase inhibitors: potential alteration of intraocular pressure control.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect may require monitoring. - Alpha‑agonist eye drops: possible need for dose adjustment. - Topical corticosteroids: may reduce Latanoprost’s IOP‑lowering action.